Piper Sandler raised the firm’s price target on Travere Therapeutics (TVTX) to $38 from $35 and keeps a Neutral rating on the shares. Following a number of Q4/FY25 pre-releases in recent weeks and ahead of Q4 reporting, the firm is taking the opportunity to review and adjust its estimates for some of its commercial names, as well as some price targets.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $44 from $43 at BofA
- Travere Therapeutics put volume heavy and directionally bearish
- Travere Therapeutics price target lowered to $43 from $47 at BofA
- Buy Rating Reaffirmed on Travere Therapeutics: Attractive Risk/Reward Despite FDA Delay and Near‑Term Catalyst Reset
- Top 5 Trending Stocks by Unusual Trading Volume, 1/14/26